Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.72 |
| ▸ | MMP12 | P39900 | 5/20 | 0.66 |
| ▸ | MMP14 | P50281 | 9/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911581 | 0.89 | MMP13 (0.78) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL4784669 | 0.87 | MMP13 (0.77) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL940885 | 0.87 | MMP13 (0.77) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942378 | 0.86 | MMP13 (0.78) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL941182 | 0.86 | MMP13 (0.78) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL4785010 | 0.86 | MMP13 (0.78) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL941464 | 0.85 | MMP13 (0.81) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942359 | 0.83 | MMP13 (0.82) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL943609 | 0.83 | MMP13 (0.80) | MMP13MMP12MMP14 | |
| SCHEMBL943611 | 0.83 | MMP13 (0.80) | MMP13MMP12MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP13 12/4885MMP12 2/4885MMP14 3/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP13 12/4885MMP12 2/4885MMP14 3/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP13 12/4885MMP12 2/4885MMP14 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.